Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients

NCT07244601 | Not Yet Recruiting FDA Device

• 1 other identifier: sarcopenia in elderly diabetic
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.Assess sarcopenia prevalence in elderly diabetic patients.
2. 2.Evaluate impact of diabetes and its medications on muscle health.
3. 3.detect effect of sacropenia on quality of life on elderly

Conditions

Sarcopenia

Outcome Measures

Primary Outcomes (2)

• Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic

  Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters

  Within 6 months from the start of recruitment.

• Assessment of muscle strength using handgrip dynamometry

  Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded.

  Within 6 months

Secondary Outcomes (1)

• Quality of life score using the SarQoL questionnaire.

  Within 6 months.

Study Arms (2)

Diabetic Group

Elderly patients with type 2 diabetes mellitus. Participants will be evaluated for the presence or absence of sarcopenia using muscle ultrasound and clinical criteria.

Diagnostic Test: muscle ultrasound

Non-Diabetic Group

Elderly patients without diabetes mellitus. Participants will also be assessed for sarcopenia using muscle ultrasound and standard diagnostic criteria.

Diagnostic Test: muscle ultrasound

Interventions

muscle ultrasound DIAGNOSTIC_TEST

Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

Diabetic Group; Non-Diabetic Group

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

1. Inclusion criteria: The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes) ●Able to give informed consent 2. Exclusion criteria: * chronic renal disease * chronic liver disese * Severe cognitive impairment * Known neuromuscular diseases affecting mobility * malignancy Data of the study will collected over one year duration from 1/2026 \_1/2027

You may qualify if:

• The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)
• ●Able to give informed consent

You may not qualify if:

• chronic renal disease
• chronic liver disese
• Severe cognitive impairment
• Known neuromuscular diseases affecting mobility
• malignancy Data of the study will collected over one year duration from 1/2026 \_1/2027

Sponsors & Collaborators

• Eman Alaa Eldean Mohamed: lead

Related Publications (1)

• Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884.

  PMID: 34904651 RESULT

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

eman alaa eldean, master degree

CONTACT

2+01098614329; emanalaa359@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: house office of Internal Medicine, Assiut University

Study Record Dates

• First Submitted: September 23, 2025
• First Posted: November 24, 2025
• Study Start: December 22, 2025
• Primary Completion (Estimated): October 20, 2027
• Study Completion (Estimated): October 20, 2028
• Last Updated: December 19, 2025

Record last verified: 2025-12